Rapid Exponential Elimination of Free Prostate-specific Antigen Contrasts the Slow, Capacity-limited Elimination of PSA Complexed to Alpha 1-antichymotrypsin from Serum
Affiliations
Objectives: To study the rates of elimination of total prostate-specific antigen (PSA-T), free PSA (PSA-F), and PSA complexed to alpha 1-antichymotrypsin (PSA-ACT) from blood after radical retropubic prostatectomy (RRP).
Methods: We obtained venous blood from 10 patients with prostate cancer who were undergoing RRP. We analyzed PSA-F and PSA-ACT and equimolar detection of both of these forms together (PSA-T) by using immunofluorometric assays. An attempt was made to fit the serum concentrations of PSA-F, PSA-ACT, and PSA-T for each patient to exponential curves by applying one- and two-compartment models for pharmacokinetic analysis.
Results: Manipulation of the prostate during RRP resulted in a 3- to 28-fold increase in PSA-F concentrations in serum. Removal of the prostate resulted in a rapid, biexponential elimination of PSA-F from serum, corresponding to a mean initial (alpha) half-life of 0.81 hours and a mean terminal (beta) half-life of 13.9 hours. Serum PSA-ACT concentrations decreased by 20% to 40% immediately after removal of the gland; the elimination after surgery was slow and nonexponential, corresponding to a mean rate of 0.8 ng/mL/day. The elimination of PSA-T reflects a combination of the elimination patterns for PSA-F and PSA-ACT.
Conclusions: The main proportion of PSA-F is rapidly eliminated from serum, possibly by glomerular filtration. PSA-F released during surgery did not form complexes with ACT, as suggested by the lack of PSA-ACT elevation in serum. The size (approximately 90 kDa) and the extensive in vitro stability of the PSA-ACT complex prevents renal clearance. The nonexponential elimination of the PSA-ACT complex is evidence of a capacity-limited process (e.g., metabolic transformation).
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.
Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P Nat Commun. 2024; 15(1):9587.
PMID: 39505858 PMC: 11541583. DOI: 10.1038/s41467-024-52472-6.
Pellegrino F, Sjoberg D, Tin A, Benfante N, Briganti A, Montorsi F World J Urol. 2023; 41(6):1489-1495.
PMID: 37209144 PMC: 10547122. DOI: 10.1007/s00345-023-04420-0.
The Role and Significance of Bioumoral Markers in Prostate Cancer.
Constantin T, Savu D, Bucur S, Predoiu G, Constantin M, Jinga V Cancers (Basel). 2021; 13(23).
PMID: 34885045 PMC: 8656561. DOI: 10.3390/cancers13235932.
Kostova M, Brennen W, Lopez D, Anthony L, Wang H, Platz E Prostate. 2018; 78(11):819-829.
PMID: 29659051 PMC: 8147660. DOI: 10.1002/pros.23539.
The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
Maccini M, Westfall N, Van Bokhoven A, Lucia M, Poage W, Maroni P Prostate. 2018; 78(7):506-511.
PMID: 29460452 PMC: 6237549. DOI: 10.1002/pros.23495.